Newly identified compound can thwart protein implicated in Parkinson’s disease

 

Newly identified compound can thwart protein implicated in Parkinson’s disease

Newly identified compound can thwart protein implicated in Parkinson’s disease.

Sergey Brin, the co-founder of Google, has an increased risk of developing Parkinson’s disease because he harbors a mutation in a protein called Leucine-rich repeat kinase 2, or LRRK2. The protein is viewed as a promising drug target to treat Parkinson’s, a progressive neurological disorder, but it is not possible to track LRRK2 activity in the brain, making the search for targeted therapies against the disease challenging.

In a new study, researchers now provide evidence for a way to measure LRRK2 activity—and a new compound that can block the damaging effects of the protein in rodent neurons.